Last update Dec. 28, 2021

Dobutamine Hydrochloride

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a derivative of isoproterenol with beta-1 agonist sympathomimetic action that is used to treat cardiac decompensation in patients with organic heart disease or from cardiac surgery. Administration by intravenous infusion.

Since the last update we have not found any published data on its excretion in breast milk.

Its very short half-life (elimination half-life: 2 minutes) make it highly unlikely that significant quantities will pass into breast milk. (Kearney 2018)

Its null oral bioavailability prevents the pasage to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability. (Kearney 2018)

Expert authors consider the use of this medication to be probably compatible during breastfeeding. (Hale, Kearney 2018, Briggs 2015)

Alternatives

We do not have alternatives for Dobutamine Hydrochloride since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dobutamine Hydrochloride in other languages or writings:

Group

Dobutamine Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Dobutamine Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 338 daltons
VD 0.2 l/Kg
pKa 10.14 -
Tmax 0.17 hours
0.03 hours

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on March 17, 2022 Full text (link to original source)
  2. Pfizer. Dobutamine. Drug Summary. 2019 Full text (in our servers)
  3. Kearney L, Wright P, Fhadil S, Thomas M. Postpartum Cardiomyopathy and Considerations for Breastfeeding. Card Fail Rev. 2018 Abstract Full text (link to original source) Full text (in our servers)
  4. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  5. AEMPS. Dobutamina. Ficha técnica. 2012 Full text (in our servers)

Total visits

4,170

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM